Synthesis, computational studies and enzyme inhibitory kinetics of substituted methyl[2-(4-dimethylamino-benzylidene)-hydrazono)-4-oxo-thiazolidin-5-ylidene]acetates as mushroom tyrosinase inhibitors. 2017

Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
Department of Chemistry, Quaid-i-Azam University, 45320 Islamabad, Pakistan.

The present article describes the synthesis and enzyme inhibitory kinetics of methyl[2-(arylmethylene-hydrazono)-4-oxo-thiazolidin-5-ylidene]acetates 5a-j as mushroom tyrosinase inhibitors. The title compounds were synthesized via cyclocondensation of thiosemicarbazones 3a-j with dimethyl but-2-ynedioate (DMAD) 4 in good yields under solvent-free conditions. The synthesized compounds were evaluated for their potential to inhibit the activity of mushroom tyrosinase. It was unveiled that compounds 5i showed excellent enzyme inhibitory activity with IC50 3.17µM while IC50 of standard kojic acid is 15.91µM. The presence of heterocyclic pyridine ring in compound 5i play important role in enzyme inhibitory activity as rest of the functional groups are common in all synthesized compounds. The enzyme inhibitory kinetics of the most potent derivative 5i determined by Lineweaver-Burk plots and Dixon plots showed that it is non-competitive inhibitor with Ki value 1.5µM. It was further investigated that the wet lab results are in good agreement with the computational results. The molecular docking of the synthesized compounds was performed against tyrosinase protein (PDBID 2Y9X) to delineate ligand-protein interactions at molecular level. The docking results showed that the major interacting residues are His244, His85, His263, Val 283, His 296, Asn260, Val248, His260, His261 and Phe264 which are located in active binding site of the protein. The molecular modeling demonstrates that the oxygen atom of the compound 5i coordinated with the key residues in the active site of mushroom tyrosinase contribute significantly against inhibitory ability and diminishing the human melanin synthesis. These results evident that compound 5i is a lead structure in developing most potent mushroom tyrosinase inhibitors.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000363 Agaricales An extensive order of basidiomycetous fungi whose fruiting bodies are commonly called mushrooms. Agaricaceae,Mushrooms,Agaricale,Mushroom
D014442 Monophenol Monooxygenase An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1. Dopa Oxidase,Phenoloxidase,Tyrosinase,Cresolase,Phenol Oxidase,Phenoloxidase A,Phenoloxidase B,Monooxygenase, Monophenol,Oxidase, Dopa,Oxidase, Phenol
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D053778 Thiazolidines Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES. Thiazolidine
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
August 2013, Archiv der Pharmazie,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
June 2018, Journal of agricultural and food chemistry,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
September 2019, Bioorganic chemistry,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
October 2017, European journal of medicinal chemistry,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
April 2021, Molecules (Basel, Switzerland),
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
September 2023, Current organic synthesis,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
January 2013, Acta crystallographica. Section C, Crystal structure communications,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
July 2021, Archiv der Pharmazie,
Pervaiz Ali Channar, and Aamer Saeed, and Fayaz Ali Larik, and Muhammad Rafiq, and Zaman Ashraf, and Farukh Jabeen, and Tanzeela Abdul Fattah
August 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!